key: cord-0772468-b6kfw2b6
authors: Carter, Rickey E.; Theel, Elitza S.; Breeher, Laura E.; Swift, Melanie D.; Van Brunt, Nathan A.; Smith, Windell R.; Blanchfield, Lorrie L.; Daugherty, Elizabeth A.; Chapital, Alyssa B.; Matson, Kathleen M.; Bews, Katherine A.; Johnson, Patrick W.; Domnick, Robert A.; Joyce, Diane E.; Geyer, Holly L.; Granger, Dane; Hilgart, Heather R.; Turgeon, Coleman T.; Sanders, Karen A.; Matern, Dietrich; Nassar, Aziza; Sampathkumar, Priya; Hainy, Caitlin M.; Orford, Robert R.; Vachon, Celine M.; Didehban, Roshanak; Morice, William G.; Ting, Henry H.; Williams, Amy W.; Gray, Richard J.; Thielen, Kent R.; Farrugia, Gianrico
title: Prevalence of SARS-CoV-2 Antibodies in a Multistate Academic Medical Center
date: 2021-03-26
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2021.03.015
sha: 1c2b0ed207da06cd2e4dbe20b6578d2d42cacc09
doc_id: 772468
cord_uid: b6kfw2b6

Objective To estimate the seroprevalence of SARS-CoV-2 antibodies in healthcare personnel. Methods The Mayo Clinic Serology Screening Program was created to provide a voluntary, two-stage testing program for SARS-CoV-2 antibodies to healthcare personnel. The first stage utilized a dried blood spot screening test initiated on June 15, 2020. Those participants identified as reactive were advised to have confirmatory testing via a venipuncture. Venipuncture results through August 8, 2020 were considered. Consent and authorization for testing was required in order to participate in the screening program. This report, which was conducted under an institutional review board approved protocol, only includes employees who have further authorized their records for use in research. Results A total of 81,113 healthcare personnel were eligible for the program, and of these 29,606 participated in the screening program. A total of 4,284 (14.5%) of the dried blood spot test results were “reactive” and warranted confirmatory testing. Confirmatory testing was completed on 4,094 (96%) of the screen reactive with an overall seroprevalence rate of 0.60% (95% CI: 0.52% to 0.69%). Significant variation in seroprevalence was observed by region of the country and age group. Conclusions The seroprevalence for SARS-CoV-2 antibodies through August 8, 2020 was found to be lower than previously reported in other health care organizations. There was an observation that seroprevalence may be associated with community disease burden.

The COVID-19 pandemic has placed unprecedented pressures on health care organizations and citizens around the world. Mayo Clinic, which spans clinical operations in Arizona, Florida, Minnesota, Iowa and Wisconsin, like many other health care organizations, quickly adapted to the emerging demands to provide high quality care while working to educate and protect the workforce.

Personal protective equipment (PPE) strategies specific to the patient, environment, and care being provided were implemented to protect the workforce. In addition, to reduce the likelihood of disease transmission across Mayo Clinic, a large percentage of nonpatient-facing employees were transitioned to remote work. remote work locations. Large scale testing using venipuncture-collected serum specimens was deemed infeasible due to the clinical practice responsibilities for emergent and routine services and the resources (eg, time, phlebotomists, physical space) required to obtain samples from over 80,000 potential participants. Thus, a two-stage testing approach was designed and implemented with a robust internal communications campaign to ensure awareness of the opportunity for HCP serology testing.

The first stage of serologic testing utilized a dried blood spot (DBS) collection method. Unlike Figure 1 where the geographic region was coded to reflect the test location for the DBS test, these results group HCP based on their home state location. Across the enterprise, prevalence was higher among younger HCP (P<.001) and did not differ by sex (P=.30).

The seroprevalence of SARS-CoV-2 antibodies was estimated to be 0.60% for the entire Mayo

Clinic enterprise through August 8, 2020. There was significant geographic variation, with areas undergoing greater community disease transmission and burden being associated with higher seroprevalence among HCP. Notably, in the broader analysis that looked at all prior SARS-CoV-2 testing, including RT-PCR and prior serologic test results, the estimated prevalence for the enterprise was higher at 1.08%.

The associated trend of seroprevalence with geographic location in the data was to be expected. The Arizona test sites were experiencing the highest COVID-19 case rates across the Mayo Clinic enterprise, during the period of the Serology Screening Program, consistent with a surge in community transmission. Mayo Clinic in Florida was located in a state that consistently had some of the highest number of community cases in the country during the study period.

The association with age group showed younger HCP to be more likely to have prior infection.

While the available records for this report did not include location of suspected exposure state. Panels C and D break th e results dow n b y age groups an d sex, respectively. Error bars are 95% score confid ence intervals. Percentages reported in each bar is th e estim ated seroprevalence. For each category, th e total sam ple size is also given . 

Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2

Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area

Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network -13 Academic Medical Centers

SARS-CoV-2 seroprevalence in COVID-19 hotspots. The Lancet

Estimated SARS-CoV-2 Seroprevalence in the US as of

Risk of SARS-CoV-2

Transmission Among Coworkers in a Surgical Environment

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers